Navigation Links
New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan
Date:10/21/2010

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan -- LOURES, Portugal, October 21, 2010 /PRNewswire/ --


Advanced Search Search

  
Close
  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Biotechnology, Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services Click to view news release full screen  

New Influenza Drug Inavir(R) TwinCaps(R) Launched in Japan

 

LOURES, Portugal, October 21, 2010 /PRNewswire/ -- Hovione has been advised by Daiichi Sankyo Company Ltd that Inavir(R) has been launched in Japan.

Inavir(R) is an inhalation powder which is delivered by the TwinCaps(R) inhaler to treat influenza. TwinCaps(R) was specifically designed by Hovione for this indication and is licensed to Daiichi Sankyo and to Biota Holdings Ltd.

Daiichi Sankyo has demonstrated that one 40mg dose of Inavir(R) active ingredient, laninamivir octanoate, is as effective as oseltamivir, a drug which needs to be taken over the course of 5 days. Daiichi Sankyo has announced it plans to supply the Japanese market with 4 million packs by end of March 2011, of which 2 million will be supplied by end of December 2010. The reimbursement price of the pack for adult treatment has been set at JPY 4161 (approx. EUR36; US$50).

TwinCaps(R) has been designed for extreme ease of use and very low cost. Daiichi Sankyo and Biota are responsible for licensing Ianinamivir.

About Hovione

Hovione is a leading developer of inhaled drug products, with experience in anti-virals and proteins delivered by inhalation, as well as inhaler development. It is an international company with 51 years' experience in Active Pharmaceutical Ingredient integrated development and compliant manufacture, from molecule to unit dose. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione: please visit the Hovione site at http://www.hovione.com or contact Corporate Communications Isabel Pina +351-21-982-9362 e-mail: ipina@hovione.com
'/>"/>

SOURCE Hovione
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. GenVec Receives Second-Year Funding From SAIC for HIV and Influenza Vaccine Development
2. Hoviones TwinCaps(R) Dry-powder Inhaler Approved in Japan as Part of Inavir(R) Influenza Treatment
3. FDA Accepts Sanofi Pasteur File Submission for Novel Influenza Vaccine Delivered by Intradermal Microinjection
4. Consumers Encouraged to Get Immunized Against Influenza
5. FDA Approves Vaccines for the 2010-2011 Influenza Season
6. NOVAVAX Announces Issuance of Key U.S. Patent for Influenza Virus-Like Particle (VLP) Vaccines
7. IDRI and PATH Enter into Research Collaboration Agreement to Evaluate Novel Adjuvants to Enhance Pandemic Influenza Vaccines
8. Novavaxs Seasonal Influenza VLP Vaccine Candidate Shows Positive Results in a Phase II Clinical Trial in Older Adults
9. Adamas Pharmaceuticals TCAD Therapy Demonstrates Broad Spectrum Activity Against Susceptible and Resistant Strains of Influenza in Animal Models
10. AmpVacs a Broadly Protective Synthetic Influenza A Vaccine
11. NOVAVAX Reports Additional Positive Data from Its Trivalent Seasonal Influenza (VLP) Vaccine Clinical Study in Healthy Adults
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  CVS Health (NYSE: CVS ... in Santa Clara County, CA , ... the Santa Clara University campus. CVS Pharmacy stores and ... patients against the disease. Students at Santa Clara University ... vaccinated. In addition, anyone who has had close contact ...
(Date:2/10/2016)... 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... that it has filed a patent application directed to ... --> --> The ... of Ceplene (histamine dihydrochloride) in combination with immune checkpoint ... the efficacy of Ceplene and IL-2 therapy in patients ...
(Date:2/10/2016)... 10, 2016  Astellas Pharma Inc. (TSE: 4503, President ... that it has successfully completed, through its indirect wholly-owned ... purchase all issued and outstanding shares of common stock ... Paul Wotton , "Ocata") for a price of ... ("Tender Offer"). Astellas commenced the Tender Offer on November ...
Breaking Medicine Technology:
(Date:2/10/2016)... California (PRWEB) , ... February 10, 2016 , ... ... are working together to expand dental health services to the developmentally disabled in ... We Care Dental’s operations to a new facility at 71-949 Highway 111, Suite ...
(Date:2/10/2016)... ... 10, 2016 , ... Compliancy Group LLC is pleased to ... throughout the country. The Guard was specifically designed to handle each element required ... regulatory updates, and compliance coaching. , In addition to meeting the compliance needs ...
(Date:2/10/2016)... CO (PRWEB) , ... February 10, 2016 , ... Dr. ... announce the practice is now accepting new dental patients and families in the North ... exceptional dental care services from cleanings to cosmetic dentistry, and all in the most ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading medical technology ... quarter and full year ended December 31, 2015 on Monday, February 29, 2016 after ... the investment community following the release at 4:30 PM ET. Investors interested in participating ...
(Date:2/10/2016)... ... February 10, 2016 , ... A ... Safety Congress and Expo event March 9-11, 2016. Hosted by Ohio's Bureau of ... , As the longest running and largest worker's compensation event in Ohio, ...
Breaking Medicine News(10 mins):